Related by context. All words. (Click for frequent words.) 65 GRNVAC1 64 Phase #b/#a clinical 63 subcutaneous formulation 63 Bezielle 63 AVAX 63 YONDELIS 63 MAGE A3 ASCI 63 RhuDex ® 62 liposomal formulation 62 IMA# 62 Phase III confirmatory 62 fosbretabulin 62 OvaRex ® MAb 62 ruxolitinib 62 vidofludimus 62 tanespimycin 62 G#DT 62 TELCYTA 62 Panzem R NCD 62 ganetespib 62 Allovectin 7 62 radiation sensitizer 62 phase IIb clinical 62 eniluracil 62 PANVAC VF 62 orally dosed 62 PDE4 inhibitor 61 depsipeptide 61 PSMA ADC 61 antibody MAb 61 ADVEXIN 61 MT# MEDI 61 BiovaxID 61 Xcellerated T Cells 61 OncoVEX 61 Capesaris 61 Bendamustine 61 orally administered inhibitor 61 IIa trial 61 EOquin TM 61 Angiocept 61 Degarelix 61 immunotherapeutic vaccine 61 somatostatin analogue 61 dose escalation clinical 61 Telatinib 61 ixabepilone 61 EGS# 61 OncoVEX GM CSF 61 QLT# 61 Onalta ™ 61 DermaVir Patch 60 PNP inhibitor 60 Traficet EN 60 volociximab 60 CoFactor 60 Phase IIIb clinical 60 PrevOnco 60 randomized controlled Phase 60 PrevOnco ™ 60 mertansine 60 docetaxel Taxotere ® 60 phase IIa clinical 60 BRAF inhibitor 60 thymalfasin 60 oral ridaforolimus 60 RhuDex TM 60 PEGylated interferon 60 Kahalalide F 60 paclitaxel poliglumex 60 bevacizumab Avastin ® 60 Phase #b/#a trial 60 ONCASPAR 60 pan HDAC inhibitor 60 MVax 60 immunomodulatory therapy 60 immunomodulator 60 lymphoid malignancies 60 dasatinib Sprycel 60 Tarceva TM 60 PEG SN# 60 Metastatic Melanoma 60 AAG geldanamycin analog 60 Irinotecan 60 cetuximab Erbitux R 60 Civacir 60 forodesine 60 NOX E# 60 Cloretazine R VNP#M 60 receptor tyrosine kinase inhibitor 60 Dacogen injection 60 humanised monoclonal antibody 60 investigational immunotherapy 60 thalidomide Thalomid 60 Pralatrexate 60 drug conjugate 60 StemEx 60 EndoTAG TM 60 HCD# [002] 60 PI3K/Akt pathway inhibitor 60 Liposomal 60 liposomal doxorubicin 60 Initiated Phase 60 generation purine nucleoside 60 TG# [001] 59 Aplidin R 59 preclinically 59 DEB# 59 Pertuzumab 59 subcutaneous SC 59 HuMax CD4 59 cilengitide 59 pegfilgrastim 59 Initiate Phase 59 sunitinib Sutent 59 registrational trial 59 elacytarabine 59 Nanobody 59 AQ4N 59 PEG IFN 59 EOquin 59 trabectedin 59 targeting CD# 59 Copegus ribavirin 59 Phase Ib study 59 Altastaph 59 ALN PCS 59 Phase 2a trial 59 erlotinib Tarceva ® 59 Yondelis ® 59 targeted radiotherapeutic 59 intratumoral injection 59 relapsing multiple sclerosis 59 HuMax EGFr 59 BrachySil TM 59 BiTE antibody 59 Teysuno 59 SinuNase TM 59 Neuvenge 59 targeted antifolate 59 subcutaneously administered 59 Dalbavancin 59 BRIM2 59 LEUKINE 59 NSABP B 59 dose escalation Phase 59 Onconase 59 EndoTAG TM -1 59 Neulasta ® 59 Multimeric 59 Neupogen ® 59 FavId 59 satraplatin Phase 59 MEK inhibitor 59 Recombinant Human 59 Granulocyte Colony Stimulating Factor 59 Panzem R 59 dasatinib Sprycel ® 59 MVA MUC1 IL2 59 Simulect 59 histone deacetylase HDAC inhibitor 59 AP# [003] 59 humanized anti 59 GVAX R 59 OvaRex R 59 HGS# 59 BCR ABL inhibitor 59 BiTE R 59 VitiGam 59 bortezomib Velcade R 59 hypoxia activated prodrug 59 Sym# 59 huN# DM1 59 MyVax R 59 APOPTONE 59 sorafenib Nexavar 59 Phase IIb clinical trials 59 Panzem NCD 59 telomerase therapeutic 59 teriflunomide 59 TroVax ® 59 pertuzumab 59 Glybera 59 BAY #-# 59 PEGylated Fab fragment 59 nucleoside analog 59 EndoTAG 59 Azacitidine 59 SNT MC# 59 Allovectin 7 ® 59 Alferon N 59 trastuzumab DM1 59 Solorel 59 Phase #b/#a 59 trastuzumab DM1 T DM1 59 Files Investigational 59 Phase IIb III 59 Lovaxin C 59 cutaneous T 59 IMC #B 58 Initiate Clinical Trial 58 confirmatory Phase III 58 docetaxel Taxotere R 58 vinorelbine tartrate 58 mitomycin 58 systemic RNAi therapeutic 58 Blinatumomab 58 CCX# 58 TKM ApoB 58 cetuximab Erbitux ® 58 HuMax CD# 58 Evoltra ® 58 Kinoid 58 CIMZIA TM 58 KNS # 58 MabCampath 58 PKC# 58 Allovectin 7 R 58 IMGN# 58 humanized monoclonal 58 acyclovir Lauriad ® 58 beta 1a 58 Fx #A 58 Guanilib 58 orally bioavailable 58 PRT# 58 AOP Orphan 58 Xyfid TM 58 busulfan 58 SCH # 58 INCB# [002] 58 YONDELIS R 58 Phase Ib II 58 inhibitor RG# 58 alvespimycin 58 ASONEP 58 OMP #M# 58 ponatinib 58 immunoconjugate 58 intravesical instillation 58 oral prodrug 58 INCB# [001] 58 TMC# [002] 58 Tamibarotene 58 ongoing Phase 1b 58 polymerase inhibitor 58 UPLYSO 58 ChronVac C ® 58 phase IIb III 58 Micromet BiTE 58 ATL# [001] 58 inhaled AAT 58 chimeric monoclonal antibody 58 FIRMAGON R 58 Azedra 58 immunotherapeutic 58 Vitaxin 58 docetaxel Taxotere 58 CEQ# 58 decitabine 58 multikinase inhibitor 58 LHRH 58 OXi# 58 Proxinium TM 58 Factor VIIa 58 CBLC# 58 BiTE 58 seliciclib CYC# 58 antibody MT# 58 Phase IIB 58 Anavex #-# 58 XOMA 3AB 58 Glybera R 58 JAK inhibitor 58 methylnaltrexone 58 Velcade bortezomib 58 JAK1 58 gemcitabine Gemzar ® 58 Loramyc R 58 DAVANAT 58 XL# XL# 58 PXD# 58 PegIFN 58 Aflibercept 58 PEGylated anti 58 CCR5 antagonist 58 Genasense ® 58 TLK# 58 Cimzia ® certolizumab pegol 58 Xanafide 58 budesonide MMX 58 ZYBRESTAT TM 58 thrombin inhibitor 58 HDAC Inhibitor 58 oncolytic vaccine 58 bispecific antibody 58 L BLP# 58 perifosine 58 Clolar ® 58 anti CD3 58 relapsed refractory multiple myeloma 58 Polymer Microspheres 58 NPC 1C 58 Alocrest 58 ALN TTR 58 Amplimexon 58 MedPulser 58 registrational 58 IAP inhibitors 58 MGd 58 HGS ETR2 58 GW# [003] 58 irreversible inhibitor 58 LEAPS TM 58 novel mTOR inhibitor 58 phase IIa 57 Personalized Immunotherapy 57 reslizumab 57 phase Ib 57 radiolabeled 57 Dendritic Cell 57 multicenter Phase II 57 Aplidin 57 Dual Opioid 57 ATryn ® 57 dose escalation trial 57 PDX pralatrexate 57 ChronVac C R 57 Amrubicin 57 TransVax tm 57 lorvotuzumab mertansine 57 GLP toxicology studies 57 Pharmacokinetics PK 57 ZACTIMA 57 Interferon alfa 57 DermaVir 57 Virulizin ® 57 intranasal formulation 57 galiximab 57 TBC# 57 TEMODAL 57 Diamyd ® 57 histone deacetylase inhibitor 57 Phase IIb Trial 57 VITAL Trial 57 VNP#M 57 CD3 monoclonal antibody 57 Phase III randomized controlled 57 murine monoclonal antibody 57 anti CTLA 57 StemEx R 57 PF # [001] 57 Cloretazine 57 multicenter Phase III 57 selective immunoproteasome inhibitor 57 Campath alemtuzumab 57 Phase 1a clinical 57 Somatuline R Autogel R 57 preclinical efficacy 57 Clevudine 57 PROVENGE ® 57 bortezomib Velcade 57 Phase IIb trials 57 UVIDEM 57 Romidepsin 57 telaprevir VX 57 personalized immunotherapy 57 SEPET TM 57 pharmacokinetic PK study 57 Recurrent Glioblastoma 57 crizotinib PF # 57 PREOS R 57 HSP# inhibitor 57 injectable formulation 57 TELINTRA 57 TRO# 57 ofatumumab HuMax CD# 57 GVAX ® 57 Interferon alpha 57 Gleevec resistant 57 GV# [001] 57 REOLYSIN ® 57 torezolid phosphate 57 fluoropyrimidine 57 mRCC 57 afamelanotide 57 Poly ICLC 57 phase Ib clinical 57 multicenter Phase 57 pharmacodynamic PD 57 rindopepimut 57 Reolysin 57 Japanese Encephalitis vaccine 57 EFAPROXYN 57 virus HCV protease inhibitor 57 romidepsin 57 Chemophase 57 HGS ETR1 57 CHOP chemotherapy 57 celgosivir 57 Urocidin TM 57 palifermin 57 Fludara 57 investigational protease inhibitor 57 ularitide 57 dose cohorts 57 topical formulation 57 evaluating satraplatin 57 ADVANCE PD 57 Davanat 57 Randomised 57 Dyloject TM 57 HCV SPRINT 57 investigational humanized monoclonal antibody 57 Immunotherapeutic 57 synthetic retinoid 57 PNT# 57 mTOR inhibitor 57 including eniluracil ADH 57 Litx 57 GTC recombinant human 57 tiuxetan 57 refractory chronic lymphocytic 57 TransMID 57 oncolytic virus therapies 57 MEND CABG II 57 ELACYT 57 RhuDex 57 Cethrin 57 Spiegelmer ® 57 MVA BN 57 novel immunotherapeutic 57 Vaxfectin 57 PROSTVAC ® 57 ATPace TM 57 MORAb 57 Fludara ® 57 OPAXIO 57 JZP 57 LEP ETU 57 photoprotective drug 57 adecatumumab MT# 57 obatoclax 57 phase IIb 57 TOCOSOL Paclitaxel 57 MAb 57 IL# PE#QQR 57 Vidaza azacitidine 57 TREANDA 57 HspE7 57 cancer immunotherapies 57 ALN TTR# 57 MAA submission 57 Medidur TM FA 57 bevacizumab Avastin R 57 immunotherapeutic agent 57 paclitaxel Taxol 57 Pivotal Study 57 ISF# 57 alfa 2a 57 small molecule tyrosine 57 IMC A# 56 treatment naive genotype 56 anticancer agent 56 vemurafenib 56 Ixabepilone 56 Icatibant 56 Genasense R 56 Stimuvax R 56 Tocilizumab 56 TRX1 56 Virulizin R 56 epothilone 56 BR.# 56 Aptivus ® 56 DUROS 56 Phase 1b clinical trials 56 ceftazidime 56 XYOTAX TM 56 PEGylated 56 Trofex 56 trastuzumab Herceptin R 56 Cloretazine ® 56 imatinib Gleevec ® 56 GATTEX ® 56 Inhalation Solution 56 Phase Ib 56 Octreotide 56 Phase Ib clinical 56 vorinostat 56 Resten NG 56 Prodarsan ® 56 Pradefovir 56 valopicitabine NM# 56 proteasome inhibitor 56 novel histone deacetylase 56 GRN#L 56 Sorafenib Nexavar 56 MKC# MT 56 XmAb 56 Dapagliflozin 56 Onrigin 56 otelixizumab 56 lumiliximab 56 NeuroSTAT ® 56 rFSH 56 tubulin inhibitor 56 CLORETAZINE TM VNP#M 56 IMP# 56 Vandetanib 56 ADP receptor antagonist 56 FOLOTYN ® 56 GRASPA ® 56 Thrombin 56 dextromethorphan quinidine 56 vaccine ChronVac C 56 LB# [003] 56 5 fluorouracil leucovorin 56 Anturol TM 56 PROSTVAC TM 56 Ixempra 56 omega interferon 56 SomatoKine 56 HERCEPTIN 56 IIa clinical 56 ALGRX 56 enzastaurin 56 Ampligen r 56 Laquinimod 56 Soliris TM eculizumab 56 Pemetrexed 56 BrachySil 56 ISTODAX ® 56 Neoadjuvant 56 DCVax ® Brain 56 StaphVAX R 56 ADVEXIN clinical 56 Enzastaurin 56 PF # [002] 56 Phase Ib clinical trials 56 imatinib mesylate Gleevec 56 catheter occlusion 56 #D#C# 56 intranasal delivery 56 histamine dihydrochloride 56 Phase III TRIST 56 PDL# 56 ZYBRESTAT fosbretabulin 56 Quinamed 56 HEPLISAV TM 56 Exherin TM 56 HQK 56 Junovan TM 56 Oncaspar 56 ZOLINZA 56 rALLy clinical trial 56 T DM1 56 IRX 2 56 Zerenex Phase 56 TORISEL 56 liposome formulation 56 Phase 1b clinical 56 HIV integrase inhibitor 56 paclitaxel Taxol ® 56 IAP inhibitor 56 Qutenza TM 56 maximally tolerated dose 56 ROCKET AF 56 ZYBRESTAT 56 zalutumumab 56 ISTODAX 56 EZN 56 MEK inhibitors 56 phase IIIb 56 mapatumumab 56 demonstrated antitumor activity 56 CA9 SCAN 56 valent conjugate vaccine 56 administered subcutaneously 56 Phase 1b trial 56 Phase III multicenter 56 ARG# 56 Tanespimycin 56 lintuzumab 56 Interferon beta 56 Zelrix 56 CD# CEA 56 Ecallantide 56 NP2 Enkephalin 56 metastatic hormone refractory 56 EGFR HER2 56 Preclinical studies suggest 56 PLK1 SNALP 56 CYT# 56 Luteinizing Hormone Releasing Hormone 56 Retacrit 56 blinded randomized placebo controlled 56 DPX Survivac 56 assessing T DM1 56 INTERCEPT platelets 56 casopitant 56 MNTX 56 refractory prostate cancer 56 hA# 56 anti angiogenic agents 56 gastrointestinal stromal tumors GIST 56 PRTX 56 Androxal TM 56 Plenaxis TM 56 novel VDA molecule 56 gemcitabine cisplatin 56 viral kinetics 56 humanized monoclonal antibody 56 accumulate preferentially 56 thetreatment 56 CD# monoclonal antibody 56 Noxafil 56 radiotherapeutic 56 rilonacept 56 DepoVax ™ 56 confirmatory Phase 56 SAR# [004] 56 Aeroquin 56 Panzem 56 ribavirin RBV 56 ENMD # 56 Kepivance 56 Argatroban 56 IND submission 56 fipamezole 56 Severe Sepsis 56 huC# DM4 56 PEGylated interferon beta 1a 56 Taxotere ® 56 nab paclitaxel 56 AZILECT R 56 tremelimumab 56 GAMMAGARD 56 CDK inhibitor 56 neratinib 56 Phase IIa trial 56 Gabapentin GR 56 low dose cytarabine 56 Onco TCS 56 RiVax ™ 56 selective androgen receptor modulator 56 TYKERB 56 Morpholino 56 Pazopanib 56 Potent Inhibitor 56 phase III isavuconazole 56 dacetuzumab 56 renin inhibitors 56 MelaFind ® 56 octreotide 56 recurrent metastatic 56 Gemcitabine 56 agonistic human 56 CCX# B 56 Pivotal Phase 56 purine analog 56 Scancell 56 ARIKACE ™ 56 PFO migraine 56 vismodegib 56 Pancreas Cancer Vaccine 56 biologic therapy 56 OncoVex 56 MoxDuo 56 Pivotal Trial 55 Initiates Clinical 55 Tarvacin TM 55 Neuradiab 55 pivotal Phase III 55 carboplatin paclitaxel 55 SinuNase ™ 55 oral antiviral 55 sodium thiosulfate STS 55 somatostatin analog 55 Safinamide 55 EDEMA3 55 Carfilzomib 55 SAR# [002] 55 LBH# 55 CYC# 55 indibulin 55 immatics 55 IV Busulfex 55 amifampridine phosphate 55 octreotide implant 55 Urocidin 55 certolizumab 55 brivaracetam 55 Cx# [002] 55 initiate Phase 2b 55 Tectin TM 55 nonclinical studies 55 CINTREDEKIN BESUDOTOX 55 Solazed 55 Targretin 55 Iluvien ® 55 CD# antibody [001] 55 CIMZIA ™ 55 Asentar 55 AzaSite Plus 55 placebo controlled Phase 55 Pivotal Phase III 55 balsalazide tablet 55 denileukin diftitox 55 Ketotransdel 55 BCG refractory 55 Archexin 55 pain palliation 55 MAP# 55 LymphoStat B TM 55 Genasense 55 Interferon alpha 2b 55 Tesetaxel 55 Receives Orphan Drug Designation 55 Zybrestat 55 CRp 55 ADVEXIN p# therapy 55 Trovax 55 PS# [001] 55 rxRNA 55 subcutaneous immunoglobulin 55 Vascular Disrupting Agent 55 cMET 55 Exherin 55 Bosutinib 55 PD LID 55 dose melphalan 55 Phase III pivotal 55 etanercept Enbrel 55 AeroLEF TM 55 pegylated liposomal doxorubicin 55 biliary tract cancer 55 personalized dendritic cell 55 Randomized Phase II 55 alefacept 55 DOS# 55 Saforis 55 VIAject R 55 Decitabine 55 EGFR TKI 55 FVIIa 55 Epothilone 55 MGCD# [001] 55 PRECISE trial 55 IRESSA 55 EP #R 55 axitinib 55 vapreotide acetate 55 Phase 2a clinical trials 55 Phase 1a 55 OLpur TM H2H 55 Tyrosine Kinase Inhibitor 55 ofatumumab 55 KRN# 55 Iluvien TM 55 paclitaxel Taxol R 55 TheraCIM 55 glatiramer acetate GA 55 CRMD# 55 Combidex 55 oral taxane 55 melphalan prednisone 55 Ganciclovir 55 RNAi therapeutic targeting 55 OncoGel 55 Aurora Kinase 55 colon carcinoma 55 pentostatin 55 SUCCEED trial 55 hyaluronidase enzyme 55 Bortezomib 55 PENNVAX B 55 RE MODEL 55 Exelixis XL# 55 BEZ# 55 HuMax 55 velafermin 55 LUVENIQ 55 renin inhibitor 55 imatinib Gleevec 55 Randomized Phase 55 Advagraf 55 reteplase 55 Phase 2b Clinical Trial 55 Allovectin 7 r 55 Cleviprex TM clevidipine 55 gemcitabine carboplatin 55 Vaxfectin R formulated 55 autologous cellular immunotherapy 55 mitogen activated ERK kinase 55 cediranib 55 Phase IIA 55 sipuleucel T 55 exon skipping 55 Anticalin R 55 Trastuzumab 55 SPRYCEL ® 55 Insegia 55 fallopian tube cancers 55 non nucleoside HCV 55 Cotara R 55 recurrent GBM 55 RH1 55 boosted protease inhibitor 55 Ophena 55 II Clinical Trial 55 NPSP# 55 Angiotensin Converting Enzyme 55 IIa trials 55 Ofatumumab 55 GeoVax vaccine 55 Successfully Completes Phase 55 ARIKACE 55 Triapine R 55 Cutaneous T 55 relapsed refractory 55 ketolide antibiotic 55 concurrent chemoradiation 55 Transgene therapeutic 55 PROCHYMAL 55 TRC# 55 Intravenous CP 55 investigational 55 azacytidine 55 octreotide acetate 55 Vicinium TM 55 GHRH 55 Actilon 55 Belinostat 55 lexidronam injection 55 NOD SCID mice 55 vivo validation 55 registrational studies 55 GeneICE 55 Zenvia ™ 55 DCVax ® 55 oral methylnaltrexone 55 MIST II 55 Altropane 55 Combo Stent 55 BENLYSTA ® 55 recurrent glioblastoma multiforme 55 acyclovir Lauriad R 55 DB# [003] 55 Ceflatonin 55 sulodexide 55 rHuPH# recombinant human 55 GSK# [001] 55 OXIGON 55 ibritumomab tiuxetan 55 multi kinase inhibitor 55 anti TNF alpha 55 Curaxin CBLC# 55 Pfizer maraviroc 55 Eli Lilly Gemzar 55 tramiprosate Alzhemed TM 55 OvaRex MAb 55 MyVax ® 55 Triapine 55 Daclizumab 55 metastatic malignant 55 SinuNase 55 gefitinib Iressa 55 miconazole Lauriad R 55 BAL# [002] 55 dose escalation 55 Camvia 55 Evoltra 55 Therapeutic Vaccine 55 Omacetaxine 55 miconazole Lauriad 55 DURIN TM 55 Xeloda ® 55 micafungin 55 selective modulator 55 NeoLipid R 55 ZK EPO 55 ganaxolone 55 #I TM# 55 visilizumab 55 Phase III clinical trials 55 XL# XL# XL# 55 Aclidinium 55 Advaxis Phase 55 adefovir dipivoxil 55 Amigal 55 Cytoxan ® 55 bardoxolone 55 sodium glucose cotransporter 55 Pivotal Phase II 55 Ontak 55 HoFH 55 Maribavir 55 Annexin V 55 Hexvix ® 55 Alinia 55 Deforolimus 55 ThermoDox R 55 evaluating carfilzomib 55 2DG 55 anti CD3 monoclonal 55 novel therapeutic antibodies 55 Phase III Pivotal 55 MoxDuo IR 55 DAVANAT ® 55 ribavirin Copegus ® 55 subcutaneous PRO 55 Vaxfectin ® 55 bendamustine 55 Trial Evaluating 55 LHRH antagonist 55 Mepact 55 Dacogen decitabine 55 GVAX immunotherapy 55 Meets Primary Endpoint 55 proprietary transdermal patch 55 ATL# [002] 55 uricase 55 Prulifloxacin 55 Zevalin R Ibritumomab 55 oral proteasome inhibitor 55 relapsed MM 55 ANYARA 55 Remune 54 ascending dose 54 ATryn R 54 antiangiogenic agent 54 HCV protease inhibitor 54 oral rivaroxaban 54 Ruconest 54 GnRH antagonist 54 Rasagiline 54 Lymphoseek ® 54 immune modulation 54 castrate resistant prostate cancer 54 refractory metastatic colorectal cancer 54 Synavive 54 vinca alkaloid 54 HDL Selective Delipidation 54 NADiA ProsVue 54 evaluating Actimmune 54 Aerosurf 54 humanized antibody 54 Enhanze Technology 54 MVA HPV IL2 54 ALN HPN 54 Roflumilast 54 Tyrima 54 RAV# 54 ara C 54 Junovan 54 tezampanel NGX# 54 orally inhaled migraine 54 Chimigen TM 54 Neo Bladder Augment 54 Erlotinib 54 MOZOBIL 54 OMP #R# 54 comparator arm 54 interferon beta 1b 54 anti CD# antibodies 54 CVac 54 ORENCIA ® 54 Phase 2b clinical 54 Multiple Ascending Dose 54 erlotinib Tarceva 54 budesonide foam 54 Cyclophosphamide 54 metastatic castrate resistant 54 ALK inhibitor 54 Centralized Procedure 54 novel nucleoside analog 54 Ocrelizumab 54 Initiates Phase II 54 trastuzumab Herceptin 54 Valtropin 54 severe oral mucositis 54 oral treprostinil 54 Phase IIIb 54 BIO SET 54 pancreatic enzyme replacement 54 Phase IIa clinical 54 APEX PD 54 APTIVUS 54 ENRICH trial 54 DCVax R Brain 54 RELOVAIR ™ 54 candidate deforolimus 54 metastatic GIST 54 alemtuzumab Campath 54 eTag assays 54 cathepsin K inhibitor 54 Fodosine 54 Elitek